Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.44 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347687 | 0.88 | METAP2 (0.50) | AKR1C2AKR1C1METAP2SIRT2SLC10A6 | |
| SCHEMBL6351360 | 0.86 | METAP2 (0.55) | AKR1C2AKR1C1METAP2SIRT2SLC10A6 | |
| SCHEMBL7063908 | 0.84 | METAP2 (0.50) | AKR1C2AKR1C1METAP2SIRT2SLC10A6 | |
| SCHEMBL6353746 | 0.84 | SIRT2 (0.61) | AKR1C2AKR1C1SIRT2HTTAKR1C4 | |
| SCHEMBL6347994 | 0.84 | KCNK2 (0.52) | AKR1C2AKR1C1SIRT2KDM4EMAPK1 | |
| SCHEMBL6349003 | 0.84 | SIRT2 (0.49) | AKR1C2AKR1C1SIRT2KDM4EMAPK1 | |
| SCHEMBL6360161 | 0.82 | SIRT2 (0.59) | AKR1C2AKR1C1SIRT2HTTAKR1C4 | |
| SCHEMBL6833917 | 0.82 | MAPK1 (0.50) | AKR1C2AKR1C1METAP2SIRT2SLC10A6 | |
| SCHEMBL6356961 | 0.81 | METAP2 (0.53) | METAP2SIRT2SLC10A6KDM4EMAPK1 | |
| SCHEMBL6350888 | 0.80 | METAP2 (0.52) | METAP2SIRT2SLC10A6HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | AKR1C2 3012/4885AKR1C1 2615/4885METAP2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.